#abelacimab
LightNews LightNews
rebel-em.bsky.social
🫀 Is Abelacimab the future of AFib anticoagulation?
🧬 Novel Factor XI inhibitor
📉 >60% less bleeding vs rivaroxaban
❓Stroke protection still uncertain
🔄 Needs Phase 3 trials vs apixaban
📖 Read more: https://wp.me/pdrP8b-5se
#FOAMed
August 6, 2026 at 4:00 AM
rebel-em.bsky.social
🫀 Is Abelacimab the future of AFib anticoagulation?
🧬 Novel Factor XI inhibitor
📉 >60% less bleeding vs rivaroxaban
❓Stroke protection still uncertain
🔄 Needs Phase 3 trials vs apixaban
📖 Read more: https://wp.me/pdrP8b-5se
#FOAMed
July 11, 2026 at 1:02 PM
jamacardiology.com
Among older patients with #AtrialFibrillation, abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged ≥75 years. ja.ma/3ZZ0T0i
CRNM Bleeding for Abelacimab vs Rivaroxaban. Graph A shows bleeding rates per 100 patient-years stratified by age. Graph B shows probability of major/CRNM bleeding at text@2.3y. The rivaroxaban probability rises with age, while abelacimab remains stable.
March 23, 2026 at 12:00 PM
rebel-em.bsky.social
🫀 Is Abelacimab the future of AFib anticoagulation?
🧬 Novel Factor XI inhibitor
📉 >60% less bleeding vs rivaroxaban
❓Stroke protection still uncertain
🔄 Needs Phase 3 trials vs apixaban
📖 Read more: https://wp.me/pdrP8b-5se
#FOAMed
March 19, 2026 at 1:06 PM
rcatanho.bsky.social
Abelacimab reduce el sangrado comparado con rivaroxaban independientemente de la edad, con el potencial de una mayor reducción en el riesgo en los mayores de 75a #abelacimab #AF #bleeding jamanetwork.com/journals/jam...
Abelacimab vs Rivaroxaban in Older Individuals With AF
This randomized clinical trial examines data via prespecified analysis to evaluate the bleeding risk of the novel factor XI inhibitor abelacimab vs rivaroxaban in patients with atrial fibrillation (AF...
jamanetwork.com
February 16, 2026 at 10:26 AM
rebel-em.bsky.social
🫀 Is Abelacimab the future of AFib anticoagulation?
🧬 Novel Factor XI inhibitor
📉 >60% less bleeding vs rivaroxaban
❓Stroke protection still uncertain
🔄 Needs Phase 3 trials vs apixaban
📖 Read more: https://wp.me/pdrP8b-5se
#FOAMed
February 13, 2026 at 12:01 PM
hcplivenews.bsky.social
A prespecified analysis of the AZALEA-TIMI 71 study has revealed abelacimab's efficacy in reducing bleeding across all included age groups with atrial fibrillation. We spoke with Christian Ruff, MD, MPH, to discuss what this means for patients.

Watch now:
Abelacimab Reduces Bleeding in AF Consistently Across Age Groups, With Christian Ruff, MD | HCPLive
Ruff explains his prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, highlighting abelacimab’s efficacy and durability compared to rivaroxaban.
www.hcplive.com
February 8, 2026 at 1:00 AM
jamacardiology.com
Among older patients with #AtrialFibrillation, abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged ≥75 years. bit.ly/4alEy1P
Two graphs compare bleeding with abelacimab vs. rivaroxaban. Graph A: bar graph shows incidence rate per 100 patient-years stratified by age. Graph B: probability of major bleeding vs. age for rivaroxaban and abelacimab pooled dose.
February 6, 2026 at 2:00 PM
med-iqcardiology.bsky.social
17/What other clinical trials for FXI/XIa inhibitors are in progress?
Ongoing phase 3 trials include the following studies for abelacimab: LILAC-TIMI 76 comparing abelacimab versus placebo in AF not eligible for OAC; ASTER comparing abelacimab versus apixaban for cancer-associated VTE; MAGNOLIA comparing abelacimab versus LMWH for GI cancer-associated VTE. The following studies for milvexian are ongoing: LIBREXIA-AF comparing milvexian 100 BID versus apixaban; LIBREXIA-STROKE comparing milvexian 25 BID versus placebo for recent non-AF stroke. The OCEANIC- STROKE study is comparing asundexian 50 daily versus placebo for recent non-AF stroke. The LIBREXIA-ACS study comparing milvexian 25 mg BID versus placebo for recent ACS was stopped in November 2025.
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
15/LILAC-TIMI 76 (abelacimab phase 3):

🔹For high-risk patients with AF or atrial flutter who are unable or unwilling to use anticoagulant therapy
A figure shows the LILAC-TIMI 76 study design that included patients with high-risk AF who were given either abelacimab 150 mg SC monthly or placebo SC monthly. The efficacy outcome was ischemic stroke or systemic embolism. The safety outcome was BARC type 3c/5 bleeding. Additional inclusion criteria for the LILAC-TIMI 76 study include: Age 65-74 and a CHA2DS2VASc ≥4 or age ≥75 and a CHA2DS2VASc ≥3, at least 1 bleeding risk factor (eg, severe renal insufficiency, concurrent antiplatelet use, prior bleeding), and unsuitable for LAA closure or occlusion device
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
14/Ongoing FXI/XIa clinical studies in patients with AF:

🔹Abelacimab phase 3 LILAC-TIMI 76
🔹Milvexian phase 3 LIBREXIA-AF
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
11/Results for AZALEA-TIMI 71 (abelacimab phase 2):

🔹Stopped early—greater-than-expected reduction in bleeding events with abelacimab vs rivaroxaban
🔹Low rates of perioperative bleeding
🔹Favorable safety profile in those with CKD
A figure shows the AZALEA-TIMI 71 study design that included patients with AF who were given either abelacimab 150 mg monthly, abelacimab 90 mg monthly, or rivaroxaban 20 mg daily. The efficacy outcome was prevention of stroke and systemic embolism. The safety outcome was major bleeding events. A bar graph shows the incidence rate of major or clinically relevant nonmajor bleeding. The incidence rates were 3.2 events per 100 person-years for abelacimab 150 mg, 2.6 events per 100 person-years for abelacimab 90 mg, and 8.4 events per 100 person-years for rivaroxaban. The P value was less than .001.
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
10/Which clinical studies have investigated FXI/XIa inhibitor therapy in patients with AF so far?

🔹Abelacimab phase 2 AZALEA-TIMI 71
🔹Asundexian phase 3 OCEANIC-AF
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
9/Findings from a meta-analysis of patients undergoing knee arthroplasty:

🔹41% reduction in VTE with an FXI inhibitor
🔹59% reduction in bleeding risk with an FXI inhibitor
🔹Asundexian was not included
A figure shows the meta-analysis results for phase 2 studies in knee arthroplasty that included IONIS-FIXI-Rx, osocimab, abelacimab, and milvexian. The risk ratios favor factor XI inhibitors over low-molecular-weight heparin for reductions in venous thromboembolism and clinically relevant bleeding.
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
8/The following investigational FXI/XIa inhibitors are currently in clinical trials; none have been approved yet for use in the US or Europe.
Current factor XI/XIa drugs include monoclonal antibody abelacimab given once a month. Small molecule inhibitors include asundexian given once a day and milvexian given twice a day.
January 14, 2026 at 8:10 PM
rebel-em.bsky.social
🫀 Is Abelacimab the future of AFib anticoagulation?
🧬 Novel Factor XI inhibitor
📉 >60% less bleeding vs rivaroxaban
❓Stroke protection still uncertain
🔄 Needs Phase 3 trials vs apixaban
📖 Read more: https://wp.me/pdrP8b-5se
#FOAMed
December 26, 2025 at 1:05 PM
befast.bsky.social
January: The Factor XI Era Arrives

AZALEA–TIMI 71 (NEJM) set the tone for the year. Abelacimab showed a massive reduction in bleeding compared to rivaroxaban in patients with AFib. Still waiting on efficacy!
December 17, 2025 at 9:02 PM
jamacardiology.com
In this secondary analysis of the AZALEA-TIMI 71 RCT, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function.

ja.ma/4pA6ViK
Two graphs. Graph A: Creatinine clearance groups showing incidence rate of major/CRNM bleed (per 100 PY) for Rivaroxaban 20mg/15mg & Abelacimab. Graph B: Range of kidney function showing event probability of major/CRNM bleeding at 2 y for Rivaroxaban & Abelacimab.
December 2, 2025 at 11:00 AM
stockmaster70.bsky.social
Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone's Anthos - Endpoints News
Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and adding to Novartis' cardiovascular pipeline.
Immagine associata al post
September 14, 2025 at 5:15 AM
renalurologynews.bsky.social
Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter.
#kidneydisease #FDA www.renalandurologynews.com/news/kidney-...
Abelacimab Reduces Bleeding Risk in Atrial Fibrillation Across Kidney Function
An investigational factor XI inhibitor shows early promise for treating atrial fibrillation in patients with a degree of kidney impairment.
www.renalandurologynews.com
September 12, 2025 at 5:12 PM
renalurologynews.bsky.social
Abelacimab reduces major and minor bleeding compared with rivaroxaban for atrial fibrillation -- even in patients with reduced kidney function receiving DOAC dose adjustment.
www.renalandurologynews.com/news/kidney-... #kidneydisease
Abelacimab Reduces Bleeding Risk in Atrial Fibrillation Across Kidney Function
An investigational factor XI inhibitor shows early promise for treating atrial fibrillation in patients with a degree of kidney impairment.
www.renalandurologynews.com
September 12, 2025 at 2:46 PM
longtail-news.bsky.social
Feed: "Medical News, Health News Latest, Medical News Today - Medical Dialogues |"
By: Medha Baranwal on Sunday, September 7, 2025
Abelacimab Cuts Bleeding Risk in AF Patients Regardless of Kidney Function: AZALEA-TIMI 71 Analysis
USA: A secondar
medicaldialogues.in
September 7, 2025 at 8:10 PM
d-and-d-world.bsky.social
Novartis unveils breakthrough data at #ESC2025, from Leqvio & Entresto to pipeline assets pelacarsen & abelacimab, driving a new era in #Cardiovascular innovation. 💙

#HeartHealth #Novartis #CVDInnovation #News #Interview
Novartis sharpens focus on cardiovascular innovation at ESC 2025
Novartis exec, Dr Glaser, highlights Leqvio, pelacarsen, abelacimab, and Entresto in new data advancing cardiovascular care.
druganddeviceworld.com
September 1, 2025 at 4:09 PM
phalguniddw.bsky.social
Novartis unveils breakthrough data at #ESC2025, from Leqvio & Entresto to pipeline assets pelacarsen & abelacimab, driving a new era in #Cardiovascular innovation. 💙

#HeartHealth #Novartis #CVDInnovation #News #Interview
Novartis sharpens focus on cardiovascular innovation at ESC 2025
Novartis exec, Dr Glaser, highlights Leqvio, pelacarsen, abelacimab, and Entresto in new data advancing cardiovascular care.
druganddeviceworld.com
September 1, 2025 at 4:09 PM
jamacardiology.com
In this secondary analysis of the AZALEA-TIMI 71 RCT, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function.

#ESCCongress #WCCardio

ja.ma/47m94sm
JAMA Cardiology publication titled "Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function" includes graphs comparing bleeding events across creatinine clearance levels for Rivaroxaban and Abelacimab.
September 1, 2025 at 12:35 PM